Literature DB >> 7770925

Calcineurin activity is only partially inhibited in leukocytes of cyclosporine-treated patients.

T D Batiuk1, F Pazderka, P F Halloran.   

Abstract

Measurement of the degree of immunosuppression induced clinically by drugs such as cyclosporine is an important but elusive goal. In lymphocytes in vitro, cyclosporine (CsA) blocks the phosphatase activity of the enzyme calcineurin, preventing cytokine induction. We sought to measure the degree of calcineurin blockade in patients on CsA. Calcineurin activity was measured in peripheral blood mononuclear cells (PBL) from stable CsA-treated renal transplant patients, compared with controls. Cytokine expression was assessed by challenging ex vivo PBL with calcium ionophore A23187 (5 microM) for 60 min and measuring interferon-gamma (IFN-gamma) and interleukin 2 (IL-2) mRNA induction. In vitro, CsA inhibited both calcineurin activity and cytokine induction with an IC50 of 10-20 micrograms/L. In CsA-treated patients with therapeutic CsA levels (mean trough CsA blood level = 180 +/- 55 micrograms/L), calcineurin activity was detectable but reduced by 50% compared with controls (P < or = 0.001) and correlated with CsA trough levels (r = -0.390, P < or = 0.01). The induction of cytokine mRNA in such patients was not blocked, but was sensitive to CsA in vitro, suggesting that CsA is much less available in vivo in body fluids than it is for isolated cells in vitro. In lymphocytes of patients on CsA, calcineurin activity is reduced but 50% of the activity persists, permitting strong signals to trigger cytokine expression. Partial calcineurin inhibition may explain why the immune responsiveness of patients on CsA is reduced but still sufficient for host defense.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7770925     DOI: 10.1097/00007890-199505270-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Therapeutic drug monitoring of immunosuppressant drugs.

Authors:  A Johnston; D W Holt
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

2.  Relationship between calcineurin inhibition and plasma endothelin concentrations in cyclosporine-A-treated kidney transplant patients.

Authors:  M Büchler; P Leibenguth; C Le Guellec; A Carayon; H Watier; F Odoul; E Autret-Leca; Y Lebranchu; G Paintaud
Journal:  Eur J Clin Pharmacol       Date:  2004-11-20       Impact factor: 2.953

3.  Evidence that calcineurin is rate-limiting for primary human lymphocyte activation.

Authors:  T D Batiuk; L Kung; P F Halloran
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

4.  Hyperalgesia and edema responses induced by rat peripheral blood mononuclear cells incubated with carrageenin.

Authors:  M A De Resende; W G Pimenta Dos Rei; L S Pereira; W Ferreira; M H Perez Garcia; M M Santoro; J Nogueira de Francischi
Journal:  Inflammation       Date:  2001-10       Impact factor: 4.092

Review 5.  Methods for clinical monitoring of cyclosporin in transplant patients.

Authors:  R J Dumont; M H Ensom
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

6.  Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients.

Authors:  Bora Akoglu; Susanne Kriener; Swantje Martens; Eva Herrmann; Wolf Peter Hofmann; Vladan Milovic; Stefan Zeuzem; Dominik Faust
Journal:  Clin Exp Med       Date:  2009-03-19       Impact factor: 3.984

7.  Single-dose daily infusion of cyclosporine for prevention of Graft-versus-host disease after allogeneic bone marrow transplantation from HLA allele-matched, unrelated donors.

Authors:  Yuichiro Nawa; Masamichi Hara; Kazushi Tanimoto; Koichi Nakase; Teruhiko Kozuka; Yoshinobu Maeda
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

8.  Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible.

Authors:  T D Batiuk; F Pazderka; J Enns; L DeCastro; P F Halloran
Journal:  J Clin Invest       Date:  1995-09       Impact factor: 14.808

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.